Go Deep
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -20,713 | -2.6 | -5.05 | -0.45 | 1,420.89 |
| Oct 2026 | -20,707 | -2.6 | -5.05 | -0.45 | 1,414.72 |
| Oct 2026 | -20,786 | -2.6 | -5.14 | -0.45 | 1,440.56 |
| Oct 2026 | -20,600 | -2.5 | -4.93 | -0.45 | 1,377.16 |
| Oct 2026 | -20,757 | -2.6 | -5.11 | -0.45 | 1,428.88 |
| Oct 2026 | -21,037 | -2.8 | -5.43 | -0.45 | 1,518.96 |
| Oct 2026 | -21,008 | -2.7 | -5.39 | -0.45 | 1,505.75 |
| Oct 2026 | -21,017 | -2.7 | -5.40 | -0.45 | 1,505.53 |
| Oct 2026 | -20,928 | -2.7 | -5.30 | -0.45 | 1,483.34 |
Ultragenyx Pharmaceutical Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 214,000,000.0 | 136,000,000.0 | 207,279,000.0 | 159,933,000.0 |
| Net Profit | -92,000,000.0 | -185,000,000.0 | -128,556,000.0 | -180,413,000.0 |
| EPS | -0.9 | -1.8 | -1.3 | -1.8 |
Ultragenyx Pharmaceutical Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 673,000,000.0 | 560,000,000.0 | 434,000,000.0 | 363,329,000.0 | — |
| Net Profit | -575,000,000.0 | -569,000,000.0 | -607,000,000.0 | -707,421,000.0 | — |
| EPS | -5.8 | -6.3 | -8.2 | -10.1 | — |
Ultragenyx Pharmaceutical Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,532,000,000.0 | 1,503,000,000.0 | 1,491,013,000.0 | 1,545,444,000.0 | — |
| Total Liabilities | 1,605,000,000.0 | 1,241,000,000.0 | 1,215,599,000.0 | 1,192,950,000.0 | — |
| Total Equity | -80,000,000.0 | 255,000,000.0 | 275,414,000.0 | 352,494,000.0 | — |
Owes vs Owns
Ultragenyx Pharmaceutical Inc. owed $1.22 for every $1 it owned in Jun 2026, up from $0.77 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.22× | 1.05× | 0.83× | 0.82× | 0.77× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ultragenyx Pharmaceutical Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 44.4%Receivables 10.3%Inventory 3.4%Fixed assets (tangible) 15.9%Intangible assets 14.4%Long-term investments 3.7%Other assets 7.9%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 1.5%Payables 1.9%Other liabilities 95.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 680.0 | 610.0 | 577.2 | 747.8 |
| Receivables | 158.0 | 122.0 | 73.4 | 40.4 |
| Inventory | 52.0 | 45.0 | 34.0 | 26.8 |
| Fixed assets (tangible) | 244.0 | 266.0 | 290.6 | 259.7 |
| Intangible assets | 220.0 | 222.0 | 210.7 | 204.5 |
| Long-term investments | 57.0 | 135.0 | 199.9 | 149.0 |
| Other assets | 121.0 | 103.0 | 105.3 | 117.3 |
| Liabilities & equity | ||||
| Short-term debt | 12.0 | 10.0 | 12.6 | 11.8 |
| Long-term debt | 24.0 | 30.0 | 30.6 | 19.8 |
| Payables | 31.0 | 39.0 | 42.1 | 43.3 |
| Other liabilities | 1,538.0 | 1,162.0 | 1,130.3 | 1,118.1 |
| Shareholders' equity | -73.0 | 262.0 | 275.4 | 352.5 |
| Net tangible assets | -300.0 | 33.0 | 64.7 | 148.0 |
Ultragenyx Pharmaceutical Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -466,000,000.0 | -414,000,000.0 | -475,000,000.0 | -380,465,000.0 | — |
| Investing Activities | 236,000,000.0 | -18,000,000.0 | 168,000,000.0 | -291,652,000.0 | — |
| Financing Activities | 478,000,000.0 | 399,000,000.0 | 388,000,000.0 | 501,208,000.0 | — |